AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04132791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aspirin after awakening + placebo before bedtime
Description: determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
Study NCT02566746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chait Trapdoor caecostomie catheter
Description: implantation of the Chait Trapdoor caecostomie catheter
Study NCT02566746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chait Trapdoor caecostomie catheter
Description: implantation of the Chait Trapdoor caecostomie catheter
Study NCT02566746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation of optimal medical therapy
Description: continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
Study NCT00502216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
Study NCT00502216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
Study NCT00502216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
Study NCT02482129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LME636 60 mg/mL ophthalmic solution
Study NCT02482129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% ophthalmic solution
Study NCT02482129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LME636 Vehicle
Description: Inactive ingredients used for masking purposes
Study NCT01849861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity
Study NCT04065529 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
Description: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
Study NCT04065529 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo + ORS + Zinc supplementation
Description: placebo + ORS + Zinc supplementation
Study NCT02542761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberglass Composite foot
Description: The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
Study NCT02542761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Composite Foot
Description: All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
Study NCT03302273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal Epithelial Stem Cell Transplant
Description: Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
Study NCT00762515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush teeth two times daily for 6 weeks
Study NCT00762515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan
Description: Brush two times daily for 6 weeks
Study NCT00762515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Brush two times daily for 6 weeks
Study NCT04642014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma treatment
Description: The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity.
Study NCT02861040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02861040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02861040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT02861040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Given IV
Study NCT02286531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-(2[18F]FLUOROETHYL)-L-TYROSINE
Description: Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
Study NCT04764760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wing shaped Tensiflex prosthesis
Description: Curative inguinal hernia repair techniqque
Study NCT02712515 — intervention group
Intervention type: PROCEDURE
Intervention: Deep brain stimulation implantation surgery
Description: Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
Study NCT02712515 — intervention group
Intervention type: DEVICE
Intervention: Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips
Description: Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
Study NCT02712515 — intervention group
Intervention type: DEVICE
Intervention: FHC Guideline 4000+ system and/or Medtronic RC+S
Description: Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
Study NCT02540486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-acting insulin glargine titration web tool (LTHome)
Description: The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
Study NCT02540486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
Study NCT02540486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
Study NCT00490568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR
Description: Experimental drug
Study NCT04121442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isunakinra
Description: Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
Study NCT04121442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-(L)1 Inhibitor
Description: Monoclonal antibody targeting PD-1 or PD-L1
Study NCT03232515 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA
Description: Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
Study NCT03269760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
Study NCT03143231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
Study NCT03143231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
Study NCT04489966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
Study NCT04609189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pearlium/EffectiCal
Description: Oral administration of Pearlium/EffectiCal.
Study NCT04609189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate/vitamin D3
Description: Oral administration of Calcium Carbonate/Vitamin D3
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation A.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation B.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation C.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation D.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080-matching placebo
Description: EA1080-matching placebo.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation E.
Study NCT04223960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA1080
Description: EA1080 Formulation F.
Study NCT04278612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality improvement intervention to strengthen health service provision
Description: Quality improvement intervention comprising of regular improvement meetings based at clinics.
Study NCT04278612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention to strengthen health service provision
Description: Quality improvement intervention comprising of regular improvement meetings based at clinics.
Study NCT01612429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation
Description: Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
Study NCT01056250 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SILS cholangiography
Description: intraoperative
Study NCT02469766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Patients in this arm will undergo SWL
Study NCT02469766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semirigid URS
Description: Patients in this arm will undergo semirigid URS
Study NCT02469766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible URS
Description: Patients in this arm will undergo Flexible URS
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin Infiltration
Description: After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30% Silver Diammine Fluoride
Description: It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Flossing
Description: In this group, the patient will perform only mechanical removal of biofilm to floss daily.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Flossing
Description: In this group, the patient will perform only mechanical removal of biofilm to floss daily.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration Placebo
Description: In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin Infiltration Placebo
Description: In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
Study NCT01477385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30% Silver Diammine Fluoride Placebo
Description: Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
Study NCT02611154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
Study NCT04275622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle including optimal exercise and diet modification.
Description: The intervention group will receive diet education and be given exercise suggestion.
Study NCT04032210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual Zinc plus Arginine based toothpaste (Colgate total)
Description: Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
Study NCT04032210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc based toothpaste (Crest complete)
Description: Regimen using Zinc based toothpaste (Crest complete)
Study NCT04032210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride based toothpaste (Signal)
Description: Fluoride based toothpaste (Signal)
Study NCT01157078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks
Study NCT01157078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study NCT03187769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Olanzapine + samidorphan, daily oral dosing
Study NCT03187769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily oral dosing
Study NCT03777644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block with ropivacaine
Description: Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study NCT03777644 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral Block with Saline
Description: Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose
Study NCT03777644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine
Description: Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study NCT03777644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Description: Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study NCT04669834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: a traditional therapeutic knee rehabilitation program
Description: mini-squatting exercise and clamshell exercise
Study NCT04669834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a traditional therapeutic knee rehabilitation program
Description: mini-squatting exercise and clamshell exercise
Study NCT04669834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercise
Description: the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
Study NCT01175785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo unmanipulated umbilical cord blood transplant
Study NCT01175785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01175785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01175785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded cord blood progenitor cell infusion
Description: Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
Study NCT01175785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT01175785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT01175785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV and PO
Study NCT01175785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02116010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Phages cocktail
Description: Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
Study NCT02116010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care : Silver Sulfadiazine
Description: Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
Study NCT02116010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P. Aeruginosa, Phages cocktail
Description: Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection